Transcriptomic changes in invasive residual cancer after neoadjuvant chemotherapy in patients with triple-negative breast cancer

被引：0
|
作者：
Orozco, Javier [1 ]
Manughian-Peter, Ayla [1 ]
Gago, Francisco [2 ]
Chang, Grace [1 ]
Grumley, Janie [1 ]
Marzese, Diego [1 ]
机构：
[1] Providence St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA USA
[2] Italian Hosp Mendoza, Mendoza, Argentina
来源：
ANNALS OF SURGICAL ONCOLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
581545
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [1] Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
    Orozco, Javier I. J.
    Grumley, Janie G.
    Matsuba, Chikako
    Manughian-Peter, Ayla O.
    Chang, Shu-Ching
    Chang, Grace
    Gago, Francisco E.
    Salomon, Matthew P.
    Marzese, Diego M.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (10) : 3185 - 3193
  • [2] Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
    Javier I. J. Orozco
    Janie G. Grumley
    Chikako Matsuba
    Ayla O. Manughian-Peter
    Shu-Ching Chang
    Grace Chang
    Francisco E. Gago
    Matthew P. Salomon
    Diego M. Marzese
    Annals of Surgical Oncology, 2019, 26 : 3185 - 3193
  • [3] Residual cancer burden and neoangiogenesis after neoadjuvant chemotherapy in triple-negative breast cancer
    Miyashita, M.
    Sasano, H.
    Tamaki, K.
    Hirakawa, H.
    Ishida, T.
    Ohuchi, N.
    BREAST, 2017, 32 : S100 - S101
  • [4] Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
    Shimanuki, Yumiko
    Shimomura, Akihiko
    Yoshimura, Kenichi
    Terakado, Hiroyuki
    Shimizu, Chikako
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3521 - +
  • [5] Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
    Li, Zhijun
    Han, Yiqun
    Wang, Jiayu
    Xu, Binghe
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):
  • [6] Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy? Reply
    Mayer, Ingrid A.
    Zhao, Fengmin
    Arteaga, Carlos L.
    Symmans, William F.
    Park, Ben H.
    Burnette, Brian L.
    Tevaarwerk, Amye J.
    Garcia, Sofia F.
    Smith, Karen L.
    Makower, Della F.
    Block, Margaret
    Morley, Kimberly A.
    Jani, Chirag R.
    Mescher, Craig
    Dewani, Shabana J.
    Tawfik, Bernard
    Flaum, Lisa E.
    Mayer, Erica L.
    Sikov, William M.
    Rodler, Eve T.
    Wagner, Lynne I.
    DeMichele, Angela M.
    Sparano, Joseph A.
    Wolff, Antonio C.
    Miller, Kathy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3522 - +
  • [7] Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer
    Kern, Peter
    Von Minckwitz, Gunter
    Puetter, Carolin
    Pavlidou, Sofia
    Flach, Annika
    Kimmig, Rainer
    Rezai, Mahdi
    ANTICANCER RESEARCH, 2015, 35 (10) : 5479 - 5484
  • [8] Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constatin, Guillaume
    Ilie, Alis
    Beltjens, Francoise
    Ladoire, Sylvain
    Desmoulins, Isabelle
    Hennequin, Audrey
    Bertaut, Aurelie
    Coutant, Charles
    Causeret, Sylvain
    Ghozali, Niama
    Coudert, Bruno
    Arnould, Laurent
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [9] Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy
    Sohn, J.
    Do, K. A.
    Liu, S.
    Chen, H.
    Mills, G. B.
    Hortobagyi, G. N.
    Meric-Bernstam, F.
    Gonzalez-Angulo, A. M.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2522 - 2526
  • [10] Pathologic and immunohistochemical prognostic score in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, S. M.
    Arnould, L.
    Briot, N.
    Desmoulins, I.
    Hennequin, A.
    Kaderbhai, C.
    Bertaut, A.
    Coutant, C.
    Causeret, S.
    Loustalot, C.
    Ilie, A.
    Derangere, V.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S432 - S432
12345